Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors

Chiara Carlomagno, Elide Matano, Roberto Bianco, Carolina Cimminiello, Antonella Prudente, Clorindo Pagliarulo, Anna Crispo, Lucia Cannella, Alfonso de Stefano, Francesco Paolo D'Armiento, Sabino de Placido

Research output: Contribution to journalArticlepeer-review


The aim of the present study was to evaluate the toxicity and efficacy of the FOLFOX-4 regimen as adjuvant chemotherapy in patients with gastric cancer after radical surgery. Fifty-four patients (1 stage Ib, 6 stage II, 22 stage IIIa, 14 stage IIIb and 11 stage IV) received 8-12 cycles of FOLFOX-4 (oxaliplatin 85 mg/m2, Day 1; leucovorin 100 mg/m2 i.v., Days 1 and 2; 5-fluorouracil 400 mg/m2 i.v. bolus, Days 1 and 2 and 600 mg/m2 in 22 h i.v. continuous infusion, Days 1 and 2; every 14 days). Toxicity was recorded at each cycle according to the National Cancer Institute Common Toxicity Criteria. Disease-free (DFS) and overall survival (OS) were calculated according to the Kaplan-Meier method. Thirty-eight patients (70.4%) completed the prescribed number of cycles of chemotherapy. The toxicity was mild. Grade 3-4 neutropenia occurred in 57% of patients, thrombocytopenia and anemia in 2% of cases. Peripheral neuropathy was experienced by 46% of the patients (grade 4 in 2% of cases). Five patients experienced grade 3 gastrointestinal toxicity. After a median follow-up of 33.1 months, 17 patients relapsed and 17 succumbed to the disease. The mean observed DFS and OS were 49.7 months (range 40.7-58.8) and 57.9 months (range 49.6-66.2), respectively. At univariate analysis, females and patients who had received

Original languageEnglish
Pages (from-to)611-617
Number of pages7
JournalExperimental and Therapeutic Medicine
Issue number4
Publication statusPublished - Jul 2010


  • Adjuvant
  • Gastric cancer
  • Oxaliplatin

ASJC Scopus subject areas

  • Medicine(all)
  • Cancer Research
  • Immunology and Microbiology (miscellaneous)

Fingerprint Dive into the research topics of 'Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors'. Together they form a unique fingerprint.

Cite this